SEI Investments’s Achilles Therapeutics ACHL Stock Holding History

SEI Investments’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39,027	Closed	-$88K	–	2701
2022 Q3	$88K	Buy	39,027 +15,458	+66%	+$43.7K	﹤0.01%	2582
2022 Q2	$59K	Buy	+23,569	New	+$58.2K	﹤0.01%	2599
2021 Q3	–	Sell	-16,220	Closed	-$159K	–	2644
2021 Q2	$159K	Buy	+16,220	New	+$220K	﹤0.01%	2483

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SEI Investments's ACHL Position: Q4 2022 in Review

SEI Investments sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 39,027 shares — an estimated $88K sold.

SEI Investments first reported a position in ACHL in Q2 2021 and held it in 3 quarters. The position peaked at $159K in Q2 2021. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

SEI Investments reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
SEI Investments sold 39,027 Achilles Therapeutics shares in Q4 2022, an estimated $88K.
SEI Investments first reported a position in Achilles Therapeutics in Q2 2021 and held it in 3 quarters.
SEI Investments's Achilles Therapeutics position peaked at $159K in Q2 2021.
23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on SEI Investments's 13F filing for Q4 2022, filed 10 Feb 2023.